TrialMenopause (New York, N.Y.)2020

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.

Ginger D Constantine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.